Beam Therapeutics (BEAM) Treasury Shares (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Treasury Shares data on file, last reported at $3.3 million in Q1 2026.

• Treasury Shares for Q1 2026 came in at $3.3 million, up 8.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 8.85% YoY), and the FY2025 annual result was $2.5 million, down 1.28% from the prior year.
• Treasury Shares advanced to $3.3 million in Q1 2026 per BEAM's latest filing, from $2.5 million in the prior quarter.
• Over five years, Treasury Shares peaked at $3.4 million in Q1 2024 and troughed at $1.5 million in Q1 2022.
• A 5-year average of $2.5 million and a median of $2.6 million in 2024 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2023 and 2025: Treasury Shares soared 72.92% in 2023, then decreased 14.09% in 2025.
• A 5-year view of Treasury Shares shows it stood at $1.7 million in 2022, then soared by 72.92% to $2.9 million in 2023, then decreased by 11.97% to $2.6 million in 2024, then retreated by 1.28% to $2.5 million in 2025, then surged by 31.4% to $3.3 million in 2026.
• Business Quant data shows BEAM's Treasury Shares at $3.3 million in Q1 2026, $2.5 million in Q4 2025, and $2.8 million in Q3 2025.